1,544 results on '"Bhinder A"'
Search Results
152. Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
153. Drug Discovery and Repurposing for Retinoblastoma
154. HbE-Beta Thalassemia with Moyamoya Syndrome: A Rare Association
155. Reference range of Amniotic Fluid Index (AFI) in primigravidae with gestational age from 37 to 42 weeks in a local (Pakistani) population
156. Effect of Internal and External Concentration Polarizations on the Performance of Forward Osmosis Process
157. SIMULTANEOUS PRESENTATION OF MICHEAL AND MONDINI MALFORMATIONS IN A SINGLE PATIENT; REPORT OF A RARE CASE.
158. EFFECT OF AGEING IN PAKISTANI POPULATION ON MIDBRAIN TO PONS AREA RATIO USING MRI: A RETROSPECTIVE STUDY.
159. Let's Dive in Ultrasound-Guided Renal Biopsy Complications in the Last Decade: A Single-Institute Study.
160. Pictorial Review of Currently Available IR-Guided Procedures in Treating Portal Hypertension.
161. Development and Analysis of Polymer-Based Self-Healing Composite Embedded with Silica (SiO2) Hollow Glass Fibers.
162. PULMONARY ARTERY PSEUDOANEYRYSM: A POST-COVID COMPLICATION
163. Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors
164. Continuous non-invasive hemodynamic monitoring in early onset severe preeclampsia
165. A Genome-Wide RNAi Screen Reveals Common Host–Virus Gene Signatures: Implication for Dengue Antiviral Drug Discovery
166. Supplementary Figure 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
167. Supplementary Figure 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
168. Supplementary Tables from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
169. Supplemental Methods from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
170. Data from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
171. Supplementary Figures from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
172. Supplementary Video from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
173. Supplementary Table 4 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
174. Supplementary Figure 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
175. Supplementary Table 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
176. Supplementary Table 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
177. Supplementary Table 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
178. Challenges of experimental research in education
179. FOREWORDS BY EDITOR
180. Stressed or engaged? Addressing the mixed significance of physiological activity during constructivist learning
181. Potential time domain model with viscous correction and CFD analysis of a generic surging floating wave energy converter
182. Comparison of Inhospital Mortality, Length of Hospitalization, Costs, and Vascular Complications of Percutaneous Coronary Interventions Guided by Ultrasound Versus Angiography
183. Принципи формування іншомовної комунікативної компетентності майбутніх офіцерів ракетно-артилерійського озброєння
184. PULMONARY ARTERY PSEUDOANEYRYSM: A POST-COVID COMPLICATION
185. Continuous non-invasive hemodynamic monitoring in early onset severe preeclampsia
186. Supplementary Figure 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
187. Data from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
188. Supplementary Table 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
189. Supplementary Table 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
190. Supplementary Figure 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
191. Supplementary Tables from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
192. Supplementary Video from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer
193. Supplemental Methods from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
194. Supplementary Table 4 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
195. Supplementary Table 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
196. Supplementary Figure 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
197. Challenges of experimental research in education
198. FOREWORDS BY EDITOR
199. Justice Theory & Intention to Quit: The Case of IT/ITES & BFSI Employees
200. A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.